Hematology-Oncology Fellowship Training

Hematology-oncology fellowship is a structured graduate medical education program that prepares physicians to diagnose and treat blood disorders and malignancies as a combined specialty. The pathway builds on internal medicine residency and leads to dual board eligibility in hematology, medical oncology, or both. Understanding the training structure, accreditation requirements, and career decision points helps clarify how specialists in this field are credentialed and what scope of practice they are trained to assume.

Definition and scope

Hematology-oncology fellowship is a subspecialty training program accredited by the Accreditation Council for Graduate Medical Education (ACGME) under the Program Requirements for Graduate Medical Education in Hematology and Medical Oncology. Standard programs run 3 years, though some institutions offer 4-year tracks that incorporate a protected research year.

Fellows enter after completing a minimum 3-year internal medicine residency. Eligibility for board certification is governed by the American Board of Internal Medicine (ABIM), which administers separate certifying examinations for hematology and for medical oncology. Candidates may sit for one or both examinations, and dual certification requires meeting the clinical competency benchmarks set by ABIM for each discipline.

The combined nature of the fellowship reflects the significant overlap between malignant hematology — including leukemia, lymphoma, and myeloma — and solid tumor oncology. Institutions may structure their programs as fully integrated tracks or as parallel rotations. Per ACGME program requirements, fellows must complete defined rotations in both hematology and oncology inpatient and outpatient settings, with exposure to bone marrow and stem cell transplant services required by most accrediting benchmarks.

The broader regulatory and professional landscape that shapes oncology practice — including prescribing authority, institutional credentialing, and federal oversight of investigational agents — is covered in detail at /regulatory-context-for-oncology.

How it works

Fellowship training is organized into discrete phases. The structure below reflects the ACGME core program requirements and ABIM certification milestones:

  1. Year 1 — Core clinical rotations: Fellows rotate through inpatient hematology, inpatient oncology, the bone marrow transplant unit, and outpatient clinics. Call responsibilities begin during this period, and fellows are expected to manage acute complications including febrile neutropenia, tumor lysis syndrome, and hematologic emergencies under attending supervision.

  2. Year 2 — Subspecialty exposure and procedural competency: Rotations expand to include dedicated consultation services, disease-specific oncology clinics (such as thoracic, gastrointestinal, or breast oncology), and elective blocks in areas such as palliative care or clinical trials administration. Procedural training includes bone marrow biopsy and aspiration, lumbar puncture, and interpretation of peripheral blood smears.

  3. Year 3 — Research, scholarly activity, and advanced clinical work: ACGME requirements mandate meaningful scholarly activity, which may include clinical research, translational science, or quality improvement projects. Fellows pursuing academic careers often spend 50 to 75 percent of their third year in protected research time, though the precise allocation varies by program.

Supervision and evaluation follow the ACGME Milestones framework for Hematology-Medical Oncology (version 2.0, published by the ACGME and ABIM jointly), which defines 24 sub-competencies mapped to six core competency domains. Program directors submit semi-annual milestone assessments for each fellow to the ACGME.

Common scenarios

Three training scenarios define most fellows' experiences:

Malignant hematology concentration: Fellows at programs affiliated with large transplant centers may encounter 40 or more bone marrow transplant cases annually. These fellows develop deep exposure to conditioning regimens, graft-versus-host disease management, and cellular therapies including CAR-T cell therapy. Dual certification in hematology is the expected outcome.

Solid tumor oncology focus: Programs at National Cancer Institute (NCI)-designated comprehensive cancer centers often feature disease-specific clinics with dedicated attendings in lung cancer, breast cancer, colorectal cancer, and prostate cancer. Fellows in these programs are frequently embedded in clinical trials infrastructure and gain familiarity with molecular profiling and biomarkers used to guide targeted therapy and immunotherapy selection.

Academic research track: Physician-scientist training programs — several funded through the National Institutes of Health (NIH) K12 or T32 mechanisms — extend fellowship by 1 to 2 years to support laboratory or translational research. These tracks produce fellows with protected time to develop independent research programs before entering faculty positions.

Decision boundaries

The primary decision point facing prospective fellows is whether to pursue hematology certification, oncology certification, or both. ABIM allows candidates to sit for each examination independently after meeting the clinical experience thresholds for that discipline. Dual certification requires successful completion of both examinations and documented training in both domains — a distinction that matters for credentialing at institutions where hematology and oncology are separately privileged services.

A second boundary separates hematology-oncology from adjacent training pathways. Radiation oncology residency is a 5-year program (1 year of preliminary training plus 4 years of radiation-specific training) accredited separately and leading to certification through the American Board of Radiology — not ABIM. Surgical oncology fellowship follows general surgery residency and is credentialed through the Society of Surgical Oncology or via complex general surgical oncology certification through the American Board of Surgery. Hematology-oncology fellowship is exclusively the medical oncology and hematology pathway, with no surgical or radiation procedural scope.

A third consideration involves the match process. Fellowship positions are filled through the National Resident Matching Program (NRMP) Subspecialty Match. In recent match cycles, hematology-oncology has been among the most competitive internal medicine subspecialty matches, with applicants typically holding strong research credentials and USMLE Step scores in the upper quartile of internal medicine applicants.

The full arc of becoming an oncologist — from medical school through board certification — is outlined at /index and in the dedicated overview at becoming an oncologist.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)